Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Amgen, Inc.    AMGN

Delayed Quote. Delayed  - 07/25 10:00:00 pm
166.56 USD   +0.54%
07/25 AMGEN : UCB and Amgen submit biologics license application for Romos..
07/22 AMGEN : Announces Webcast Of 2016 Second Quarter Financial Results
07/22 AMGEN : Announces 2016 Third Quarter Dividend
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Amgen, Inc. : Amgen 1Q Profit Rises 5.2% On Broad Sales Growth

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/24/2012 | 10:40pm CEST

Amgen Inc.'s (AMGN) first-quarter earnings rose 5.2% as the biopharmaceutical company reported sales growth across many of its products, helping results beat expectations.

The company has been trying to bolster its research-and-development pipeline and grow sales of its bone-building drugs to help offset declining sales of its key anti-anemia drugs, which have slumped in recent years due to safety concerns and intensifying competition. Amgen recently completed $1.16 billion acquisition of Micromet Inc. (MITI), a deal expected to strengthen its cancer-drug research pipeline.

Amgen reported a profit of $1.18 billion, or $1.48 a share, up from $1.13 billion, or $1.20 a share, a year earlier. Excluding acquisition and restructuring-related expenses and other items, earnings were up at $1.61 from $1.34. Revenue increased 9.2% to $4.05 billion.

Analysts polled by Thomson Reuters most recently projected earnings of $1.45 on revenue of $3.93 billion.

Operating margin rose to 36.4% from 34.9%.

Combined sales of Neulasta and Neupogen, which are used to ward off infections undergoing cancer treatment, rose 9% to $1.34 billion.

The company has been counting on its new bone-building drugs, Xgeva and Prolia, to boost overall sales growth. Sales of Xgeva, a drug designed to prevent bone injuries in cancer patients, were up 14% to $153 million. Sales of Prolia, for osteoporosis in women, were up 9% to $153 million.

Shares of Amgen, which affirmed its 2012 guidance, were up 1% to $69.32 in recent after-hours trading.

-By Tess Stynes, Dow Jones Newswires; 212-416-2481; Tess.Stynes@dowjones.com

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on AMGEN, INC.
07/25 AMGEN : UCB and Amgen submit biologics license application for Romosozumab to th..
07/22 AMGEN : Announces Webcast Of 2016 Second Quarter Financial Results
07/22 AMGEN : Announces 2016 Third Quarter Dividend
07/22 AMGEN : Owen Smith to pledge equal representation of women in Labour
07/22 AMGEN : And UCB Submit Biologics License Application For Romosozumab To The FDA
07/22 AMGEN : UCB and Amgen submit FDA application for Osteoporosis drug
07/21 AMGEN : Patent Issued for Method for Culturing Mammalian Cells to Improve Recomb..
07/21DJAmgen and Allergan Study Finds Biosimilar Comparable to Herceptin
07/21 AMGEN : Announces Settlement Of Securities Litigation
07/20 AMGEN : Technical Coverage on Biotechnology Equities -- Galena Biopharma, Eleven..
More news
Sector news : Bio Therapeutic Drugs
07/25DJGILEAD SCIENCES : Sales of Hepatitis C Drugs Fall 19% -- 2nd Update
07/25DJGILEAD SCIENCES : Sales of Hepatitis C Drugs Fall 19% -- Update
07/25DJGilead Sales of Hepatitis C Drugs Fall 19%
07/25DJGILEAD SCIENCES : Sales of Hepatitis C Drugs Fall 19%
07/12DJJuno to Resume Clinical Trial of Anticancer Treatment
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
07/25 Is Biotech Finally Ready To Move Higher?
07/25 RETIREMENT STRATEGY : 5 Pharmaceutical Dividends To Buy Here
07/24 MY EARNINGS GAME PLAN : July 25-27
07/24 TOP 10 HEALTH CARE STOCKS : Which To Buy? Part 3
07/23 Biogen Q2 Plusses And Minuses
Advertisement
Financials ($)
Sales 2016 22 569 M
EBIT 2016 10 789 M
Net income 2016 7 447 M
Debt 2016 2 908 M
Yield 2016 2,41%
P/E ratio 2016 16,88
P/E ratio 2017 15,39
EV / Sales 2016 5,64x
EV / Sales 2017 5,29x
Capitalization 124 454 M
More Financials
Chart AMGEN, INC.
Duration : Period :
Amgen, Inc. Technical Analysis Chart | AMGN | US0311621009 | 4-Traders
Full-screen chart
Technical analysis trends AMGEN, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 185 $
Spread / Average Target 12%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Robert A. Bradway Chairman, President & Chief Executive Officer
Madhavan Balachandran Executive Vice President-Operations
David W. Meline Chief Financial Officer & Executive Vice President
Paul R. Eisenberg Chief Medical Officer & Senior VP-Global Medical
Frank J. Biondi Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
AMGEN, INC.2.06%124 454
GILEAD SCIENCES, INC.-14.47%115 269
CELGENE CORPORATION-10.22%83 285
REGENERON PHARMACEUTIC..-27.91%41 121
VERTEX PHARMACEUTICALS..-25.38%23 224
ACTELION LTD22.85%19 820
More Results